Lexiscan FDA Approval History
FDA Approved: Yes (First approved April 10, 2008)
Brand name: Lexiscan
Generic name: regadenoson
Dosage form: Injection
Company: CV Therapeutics, Inc.
Treatment for: Diagnosis and Investigation
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.
Development timeline for Lexiscan
| Date | Article |
|---|---|
| Apr 11, 2008 | Approval CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(regadenoson) Injection |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
